This vertical contributed another Rs 790 crore of revenue with its generic anaesthetic

products

and

over-the-counter

products.

The last piece of this vertical, the drug discovery business, is still in trial phase with a
pipeline of 13 compounds and no revenue.
The company may see its biggest growth in the near future coming from the other
two
verticals:
information
management
and
financial
services.
In May 2012, Piramal had bought US-based Decision Resources Group which does
data analytics for the healthcare industry. This contributed revenue of Rs 730 crore
in
the
nine-month
period.
The financial services business comprises a non-banking finance company and real
estate fund. This brought the company revenue of Rs 560 crore in the nine-month
period.
While the company is in the process of building these businesses, Piramal doesn't
want to let go of short-term opportunities like Vodafone to make money.
Investments done by Piramal Enterprises
Aug 2011
5.5
Rs 2,856 crore

in

Vodafone

India

in

Vodafone

India

Feb 2012
5.5
Rs 3,000 crore
Feb 2012
10
%
Rs 1,652 crore

in

Shriram

Transport

Finance

April 2013: Structured investment of Rs 550 crore in Navyuga Engineering

Company through Strategic Investment Group
April 2013: Structured investment of Rs 500 crore via convertible debentures in
Green Infra, a wind energy company backed by IDFC Private Equity